I was doing some research for a possible blog post and came across this survival graph for "early Zytiga" use in metastatic patients from the STAMPEDE trial. If I recall correctly, the 5-year survival for such patients used to be about 28%. This graph stops just short of 5-years, but close enough to make some guesses.
It looks to me like the "don't use early Zytiga" curve is heading towards 40% at 5 years. This would reflect the benefit gained from newer drugs becoming available.
The "early Zytiga" curve is heading towards the high 50s possibly as high as 60%. This would reflect the benefit of using the available drugs sooner and in combination.
This is fantastic! To me it looks like five year survival has now doubled, and there's better than a coin flip chance of living more than 5 years.